Alnylam

Alnylam ratchets up Pfizer, Moderna infringement fight on same day it scored new patent
Fierce Pharma
Wed, 07/13/22 - 08:18 pm
legal
Alnylam
Pfizer
Moderna Therapeutics
patents
vaccines
Alnylam wins FDA approval of rare disease drug in step toward profitability
BioPharma Dive
Tue, 06/14/22 - 11:14 am
Alnylam
FDA
Amvuttra
hATTR amyloidosis
With Alzheimer's in its sights, Alnylam shares data on getting siRNA to targets beyond the liver
Fierce Pharma
Tue, 06/7/22 - 09:59 am
Alnylam
siRNA
Alzheimer's disease
drug development
Pfizer shoots back at Alnylam's claims in high-stakes COVID-19 vaccine patent case
Fierce Pharma
Thu, 06/2/22 - 10:21 am
Pfizer
Alnylam
vaccines
COVID-19
patents
Alnylam shoots for the heart
EP Vantage
Thu, 05/19/22 - 10:16 am
Alnylam
Onpattro
ATTR amyloidosis
How a surprise finding made an Alnylam study one of biotech’s most ‘polarizing’ trials
BioPharma Dive
Tue, 04/26/22 - 10:31 am
Alnylam
clinical trials
Onpattro
transthyretin amyloid cardiomyopathy
Alnylam's potential fourth RNAi approval delayed three months, but impact likely to be 'modest'
Endpoints
Mon, 04/4/22 - 11:08 pm
Alnylam
RNAi
FDA
vutrisiran
The biggest launches of 2022: a reboot
EP Vantage
Mon, 02/14/22 - 10:48 am
drug launches
Eli Lilly
tirzepatide
Alnylam
vutrisiran
Roche
Vabysmo
JNJ
Carvykti
Mirati Therapeutics
adagrasib
Bristol Myers Squibb
mavacamten
deucravacitinib
SFNP 2022 – Alnylam takes heart from its Onpattro follow-on
EP Vantage
Tue, 01/25/22 - 10:41 am
Alnylam
vutrisiran
Onpattro
hereditary ATTR amyloidosis
Alnylam, awaiting key study data, builds case for its next rare disease drug
BioPharma Dive
Sat, 01/22/22 - 02:12 pm
Alnylam
ATTR
vutrisiran
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
Thu, 01/13/22 - 07:31 am
FDA
adagrasib
donanemab
faricimab
lecanemab
tezepelumab
tirzepatide
vutrisiran
Eli Lilly
Mirati Therapeutics
Roche
Chugai
Eisai
Biogen
AstraZeneca
Amgen
Alnylam
Where will Novartis spend the $21B from Roche stake sale? Alnylam buyout could be one: report
Fierce Pharma
Thu, 11/18/21 - 10:50 am
Novartis
Roche
M&A
Alnylam
What Novartis could buy with its windfall
EP Vantage
Fri, 11/5/21 - 09:40 am
Novartis
M&A
Roche
Sandoz
Aurinia Pharmaceuticals
Alnylam
Exelixis
Incyte
Eisai
Genmab
Alnylam Announces Planned CEO Leadership Transition
Yahoo Finance
Thu, 10/28/21 - 10:42 am
Alnylam
earnings
Pharma CEOs
John Maraganore
Dicerna can’t catch up with Alnylam
EP Vantage
Mon, 08/9/21 - 10:50 am
Dicerna
Primary Hyperoxaluria
Alnylam
nedosiran
Alnylam's Study on Renal Treatment Shows Promising Results In Phase III Trial
BioSpace
Mon, 08/2/21 - 11:06 am
Alnylam
RNAi
renal decline
clinical trials
lumasiran
A 'springboard' to the future: Genentech, Sanofi and Alnylam execs sound off on pharma's evolving back-to-work plans
Fierce Pharma
Wed, 05/26/21 - 12:05 am
pandemic
COVID-19
Genentech
Sanofi
Alnylam
remote work
human resources
The "Rare Disease Company Coalition" Launches to Share the Unique Challenges and Promise of Rare Disease Therapy Development to Support Continued Progress and Patient Access
Yahoo/Businesswire
Thu, 05/13/21 - 12:04 pm
Rare Diseases
Rare Disease Company Coalition
drug development
drug discovery
Acceleron
Aeglea BioTherapeutics
Agios Pharmaceuticals
Alnylam
Harmony Biosciences
Orchard Therapeutics
Orphazyme
Sarepta Therapeutics
Taysha Gene Therapies
Ultragenyx
Alnylam provides long-term look at Oxlumo, aiming to further carve out stake in PH1 market
Endpoints
Tue, 05/4/21 - 10:38 am
Alnylam
Oxlumo
Primary Hyperoxaluria
clinical trials
AAN 2021 – Helios backs Alnylam’s sunny forecasts
EP Vantage
Wed, 04/21/21 - 10:28 am
Alnylam
AAN
vutrisiran
Onpattro
hATTR amyloidosis

Pages